Informed Prostate Cancer Patient Support

Learning to Adapt - Deep Reinforcement Learning in Treatment-Resistant Prostate Cancer | bioRxiv summary of "Learning to Adapt - Deep Reinforcement Learning in Treatment-Resistant Prostate Cancer"  View ORCID Profile Kit Gallagher , View ORCID Profile Maximilian Strobl , View ORCID Profile Robert Gatenby , View ORCID Profile Philip Maini , View ORCID Profile Alexander Anderson https://www.biorxiv.org/content/10.1101/2023.04.28.538766v1.full.pdf The paper proposes a deep reinforcement learning (DRL) approach to optimize personalized cancer treatment for patients with treatment-resistant prostate cancer. The approach uses a combination of DRL algorithms and a biophysical model of prostate cancer growth to iteratively optimize a personalized treatment plan. The study shows that the proposed approach can lead to significant improvements in treatment efficacy compared to standard-of-care treatments. The authors suggest that this DRL approach can be extended to other type

Upregulation of TLR5 indicates a favorable prognosis in prostate cancer - Liang - The Prostate - Wiley Online Library The Prostate by  Hongbin Liang, Lin Zhang, Ziying Liu, Bettina Hoden, David DeRubeis, Yifan Zhang, Fen Wang, Dekai Zhang 1d Background Toll-like receptors (TLRs) are the key sensors of innate immunity for triggering immune responses against infections. TLRs are well known to be expressed and activated in innate immune cells, such as macrophage and dendritic cells, but we and others have found that some TLRs are also functional in epithelial cells. However, the role of an epithelial TLR in prostate cancer remains elusive. Methods TLR5 expression in messenger RNA

Breakthrough trial shows MRI-guided radiation can reduce prostate cancer treatment toxicity kevinmd.com Kevin Nearly 290,000 American men will be diagnosed with prostate cancer in 2023. Thankfully, the vast majority will be diagnosed with clinically localized disease and can be cured with either surgery or radiotherapy. Emerging clinical trial data have cemented stereotactic body radiotherapy (SBRT), a form of radiation in which ≤5 daily doses are delivered with high precision in generally five or fewer treatments, as a curative option for most men with localized prostate cancer. Because cure rates are so high, post-treatment quality of life (QOL) is often the major concern for patients with a new diagnosis of prostate cancer. With respect to radiotherapy of any kind, including SBRT, the major QOL impacts can be categorized into one of three domains: genitourinary (GU), gastro

Enzalutamide-ADT Cuts Risk for Disease Spread in Nonmetastatic Prostate Cancer | MedPage Today medpagetoday.com Enzalutamide-ADT Cuts Risk for Disease Spread in Nonmetastatic Prostate Cancer Mike Bassett 6–8 minutes Meeting Coverage > AUA — Combo has potential to be new standard of care in patients with high-risk BCR, expert says by Mike Bassett , Staff Writer, MedPage Today April 30, 2023 CHICAGO -- Combining enzalutamide (Xtandi) with an androgen deprivation therapy (ADT) boosted metastasis-free survival (MFS) in patients with prostate cancer at high risk for biochemical recurrence, according to the EMBARK trial opens in a new tab or window . After a median follow up of 60.7 months, the com

Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer: Expert Review of Anticancer Therapy: Vol 0, No 0

JPM | Free Full-Text | Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction

Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review - ScienceDirect

Unlocking the mystery associated with infertility and prostate cancer: an update | SpringerLink

Emerging treatment options for prostate cancer: Expert Review of Anticancer Therapy: Vol 0, No ja

Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate‐resistant prostate cancer post‐abiraterone and/or enzalutamide - Jang - The Prostate - Wiley Online Library

Unspecific 18F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer | Journal of Nuclear Medicine

Is 18F-FDG PET Needed to Assess 177Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis | Journal of Nuclear Medicine

A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer | Journal of Nuclear Medicine

Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution? | Journal of Nuclear Medicine

Toward Single-Time-Point Image-Based Dosimetry of 177Lu-PSMA-617 Therapy | Journal of Nuclear Medicine

Looking at the Future of Prostate Cancer Treatment | Journal of Nuclear Medicine

Disparities in prostate cancer diagnosis and management: recognizing that disparities exist at all junctures along the prostate cancer journey | Prostate Cancer and Prostatic Diseases

Prostate Cancer Patient Conference - UCSD-TV - University of California Television, San Diego

Prostate Cancer Promise – In The Fight Against Prostate Cancer, Your DNA May Be The Most Powerful Tool

LIVESTRONG at the Y - Personal Training for Cancer Survivors | YMCA of San Diego County ymcasd.org LIVESTRONG at the YMCA 4–5 minutes LIVE STRONG  at the YMCA of San Diego County Reaching Goals Together A supportive community is a big part of health and wellness. Our mission drives us to ensure everyone has the opportunity to learn, grow and thrive in a nurturing environment.  In It Together LIVE STRONG   at the YMCA is fully funded by donors to engage cancer survivors through an approach that focuses on the whole person - mind and body. Through this program participants work with trained Y staff to improve cardiovascular endurance and functional ability, build muscle mass and strength, and increase flexibility. In addition to physical benefits, the program also focuses on the mental and emotional well-being of survivors and their families. This creates a supportive community envir

Charles Spruck awarded $1.7M to advance “ancient virus” treatment for prostate cancer | Sanford Burnham Prebys sbpdiscovery.org Charles Spruck awarded $1.7M to advance “ancient virus” treatment for prostate cancer The approach uses ancient viruses, embedded in our genomes, to trick the body into thinking it has an infection. With the help of a new grant from the U.S. Department of Defense for more than $1.7 million, Associate Professor Charles Spruck, Ph.D. , will advance an innovative therapeutic approach for metastatic prostate cancer. Known as viral mimicry, the approach tricks the body into thinking that it has a viral infection, stimulating an immune response that can help the body fight cancer. “In viral mimicry, the body thinks there’s an infection, which kicks the immune system into high gear,” says Spruck. “With the immune system activated, cancer cells are more responsive to treatment, and tumor growth slows. All of this can happen witho

DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations | Cancer Research | American Association for Cancer Research :  aacrjournals.org DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations Gallon, John, Rodriguez-Calero, Antonio, Benjak, Andrej, Akhoundova, Dilara, Maletti, Sina, Amstutz, Ursula, Hewer, Ekkehard, Genitsch, Vera, Fleischmann, Achim, Rushing, Elisabeth J., Grobholz, Rainer, Fischer, Ingeborg, Jochum, Wolfram, Cathomas, Gieri, Osunkoya, Adeboye O., Bubendorf, Lukas, Moch, Holger, Thalmann, George, Feng, Felix Y., Gillessen, Silke, Ng, Charlotte K.Y., Rubin, Mark A., Piscuoglio, Salvatore 67–85 minutes Abstract Metastases from primary prostate cancers to rare locations, such as the brain, are becoming more common due to longer life expectancy resulting from improved tre